This study collected real-world evidence to better understand and define the relative bioavailability ratio between compounded rapamycin and generic rapamycin, with a specific focus on relative efficacy in increasing rapamycin levels in the blood (blood rapamycin levels).

Inclusion Criteria:

• Receive AgelessRx's standard Rapamycin treatment protocol
• Opted to complete at least 1 blood draw at their local Quest Lab

Exclusion Criteria:

• Not approved for current AgelessRx standard Rapamycin treatment
• History of uncontrolled disease
• Unable to complete at least 1 blood draw at their local Quest Lab

Participants who sought rapamycin prescription for longevity support, pain reduction, energy improvement, weight loss, mood improvement, sleep improvement, or oral health improvement were included in the study. To be eligible to receive AgelessRx's standard rapamycin treatment protocol, participants had to be ≥40 years of age, without a history of uncontrolled disease. All patients treated with rapamycin and opted for at least one blood draw test between May 1, 2023, and December 15, 2023, were included in this retrospective study.